Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2034118 | 0.88 | PDE10A (0.51) | PDE10A | |
| SCHEMBL14124018 | 0.79 | PDE10A (0.53) | PDE10A | |
| SCHEMBL15372491 | 0.79 | PDE10A (0.53) | PDE10A | |
| Hydrochloric Acid SCHEMBL2039304 | 0.78 | PDE10A (0.52) | PDE10A | |
| SCHEMBL2040321 | 0.72 | PDE10A (0.77) | PDE10A | |
| SCHEMBL2046574 | 0.72 | PDE10A (1.00) | PDE10A | |
| SCHEMBL15058015 | 0.72 | PDE10A (1.00) | PDE10A | |
| SCHEMBL260199 | 0.72 | PDE10A (1.00) | PDE10A | |
| SCHEMBL8738304 | 0.70 | PDE10A (0.55) | PDE10A | |
| SCHEMBL2035705 | 0.70 | PDE10A (0.61) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501795-B2 | (3-aryl-1H-1,2,4-triazol-5-yl)-linked heterocycle derivatives | H. LUNDBECK A/S (DK) | 2013-08-06 | — | — | US | disclosed |
| US-20120309764-A1 | Heteroaromatic aryl triazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309764-A1 | Heteroaromatic aryl triazole derivatives as PDE10A enzyme inhibitors | PDE5A, PDE3B, PDE3A | PDE10A 5/4885XDH 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.